Adenosine deaminase and purine nucleoside phosphorylase activity in red blood cells and peripheral blood mononuclear cells
| . | . | Erythrocytes . | Mononuclear cells . | ||
|---|---|---|---|---|---|
| ADA . | PNP . | ADA . | PNP . | ||
| Patient | Before BMT | 0.98 | 1259 | 0.71 | 3062 |
| Patient | After BMT | 17.6 ± 6.6 | 1585 ± 104 | 1176 ± 1082 | 5970 ± 2861 |
| Donor | 18.4 | 1744 | 937 | 5179 | |
| Normal levels | 63 ± 41 | 1336 ± 441 | 1197 ± 516 | 3007 ± 824 | |
| . | . | Erythrocytes . | Mononuclear cells . | ||
|---|---|---|---|---|---|
| ADA . | PNP . | ADA . | PNP . | ||
| Patient | Before BMT | 0.98 | 1259 | 0.71 | 3062 |
| Patient | After BMT | 17.6 ± 6.6 | 1585 ± 104 | 1176 ± 1082 | 5970 ± 2861 |
| Donor | 18.4 | 1744 | 937 | 5179 | |
| Normal levels | 63 ± 41 | 1336 ± 441 | 1197 ± 516 | 3007 ± 824 | |
ADA indicates adenosine deaminase; PNP, purine nucleoside phosphorylase; BMT, bone marrow transplantation.
Enzyme activities are expressed as nmol/h/mg protein. Pre-BMT patient and donor values are from single samples. Normal values and post-BMT data for the patient are given as mean ± SD. Post-BMT patient samples were obtained on 4 occasions—at 16 months, 26 months, 47 months, and 127 months after transplantation.